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Abstract
Benzophenones, frequently used as UV chemical filters, are absorbed through the skin and can exert systemic adverse effects. So
far, most of the data are related to their action on sex hormone receptors whereas potential neurotoxic effect is expected mainly on
the basis of in vitro studies. The aim of the present study was to determine concentrations of BP-2, oxidative stress and apoptosis
markers in the rat brain after topical administration of this compound. Male Wistar rats were treated dermally with BP-2
(100 mg/kg, 4 weeks), and next, blood and tissue BP-2 concentrations and oxidative stress and apoptotic markers in the frontal
cortex and hippocampus were determined. After dermal BP-2 administration, blood level of this compound was about 300 ng/ml
while in the liver and adipose tissue 1354 and 823 ng/g wt tissue, respectively. In the studied brain structures, the levels of the test
compound were from 5 to 19 ng/g tissue. In the hippocampus, where BP-2 level was about 3.5-fold lower than in the frontal
cortex, no significant changes in either oxidative stress and apoptosis markers were observed. There was also no change in
apoptosis markers in the frontal cortex but unexpectedly the oxidative stress markers were reduced. The research showed that BP-
2 passes through the blood-brain barrier but its concentration in the brain structures are much lower than in the blood. This
compound did not exacerbate oxidative stress and apoptosis markers in the hippocampus and frontal cortex, and even lowered
oxidative stress in the frontal cortex.
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Introduction
Benzophenone derivatives are most common ultraviolet (UV)
light filters used in a variety of cosmetics, like lipstics, sham-
poos, body lotions, conditioners, and hair sprays. They are
also added to the production of food packaging to protect it
from the damaging effects of sunlight. Negative effects of UV
radiation, such as generation of reactive oxygen species
(ROS), induction of DNA damage, and inhibition of skin im-
mune system function increases the risk of skin cancer devel-
opment, so the use of UV filters is required for protection of
the skin. However, the existing information on potential
adverse effects of chemical UV filters is incomplete and in-
sufficient to reliably assess which of the currently used com-
pounds are safest.
Human exposure to UV filters occurs mainly through skin
absorption but also by consuming contaminated food (Jiang
et al. 1999; Gustavsson Gonzalez et al. 2002). Due to wide-
spread use of benzophenones, their high concentrations are
detected in the waters of lakes and rivers as well as in waste-
water and tissues of aquatic organisms, especially in fish fat
(Fent et al. 2010). For many years, it was believed that the
compounds used as chemical UV filters might only have ad-
verse effects on the skin, i.e., might cause irritation or allergic
contact dermatitis. However, subsequent studies showed that
significant amounts of these compounds were absorbed by the
skin, entered the circulation, and could exert systemic effects,
mainly on the endocrine system function. Benzophenones be-
long to the group of endocrine-disrupting chemical (EDCs)
because they show an affinity for the steroid hormone recep-
tors and interfere with gonadal function. Most of the in vitro
and in vivo data indicate estrogenic and antiandrogenic effects
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of these compounds, and some reports show that benzophe-
nones also interfere with thyroid function. Estrogenic effect of
BP-2 on the uterine weight, luteinizing hormone, and meta-
bolic markers was demonstrated in ovariectomized rats (Jarry
et al. 2004; Seidlová-Wuttke et al. 2004, 2005; Schlecht et al.
2006). Particularly unfavorable effects, like other EDCs,
benzophenone-2 seems to exert on the development and func-
tion of testes. It has been found that human urinary concen-
tration of benzophenone-2 is associated with decrease in se-
men quality and fertility (Buck Louis et al. 2015) and that
administration of BP-2 to pregnant mice induce hypospadias
in the male offspring and this effect is mediated through the
estrogen receptors (Hsieh et al. 2007). In addition to the estro-
genic effect, the administration of the BP-2 affects thyroid
hormone secretion probably through inhibition of the thyroid
peroxidase (TPO) activity (Schmutzler et al. 2007).
Benzophenones disrupting the function of sex and thyroid
hormones may affect almost all systems of the body, because
estrogen and thyroid receptors occur in many cells. Central
nervous system cells also contain receptors for the sex and
thyroid hormones, so benzophenones can impair their func-
tion. The role of estrogens in regulating the function of nerve
cells, especially their neuroprotective effects, is well known
(Engler-Chiurazzi et al. 2017). Thyroid hormones are essential
for the proper functioning of the brain primarily during the
developmental period but current research indicates that also
in adults, some genes, especially those involved in regulating
brain metabolism and intracellular signal pathways, remain
sensitive to the action of these hormones (Vallortigara et al.
2008;Wang et al. 2015b). Thus, benzophenones impairing the
sex and the thyroid hormone function in the brain can affect
viability of the CNS cells and thus exacerbate neurodegener-
ative processes. This possibility is confirmed by results of
in vitro studies. Previously, we showed that various chemical
UV filters, including BP-2, decreased viability and increased
the process of apoptosis in SH-SY5Y human neuroblastoma
cells (Broniowska et al. 2016). Although, BP-2 exerted ne-
crotic effect in relatively high concentration of about 10 μM;
however, the pro-apoptotic action of this compound was al-
ready evident when it was used in much lower concentrations
of about 0.1 μM, so concentrations that theoretically may be
present in vivo. Taking into account the lipophilic nature of
benzophenones, they should pass through the blood-brain bar-
rier, but up to now, the level of any of the benzophenones in
the central nervous system in in vivo models is not known. As
far as BP-2 is concerned, there is even no data about its ab-
sorption through the skin and blood levels after dermal appli-
cation. Generally, it is estimated that about 10% of the dermal
dose of benzophenones is absorbed into the systemic circula-
tion (Jiang et al. 1999; Gustavsson Gonzalez et al. 2002).
Among benzophenones, the most data concerns absorption
and blood level of benzophenone 3 in humans and experimen-
tal animals. After dermal application, benzophenone 3
concentration in human blood is up to 250–300 ng/ml and it
has been shown that in the liver, kidneys, spleen, and testes of
rats, the level of this compound can be up to 10-fold higher
than in serum (Okereke et al. 1994; Tarazona et al. 2013).
Since there are no data on the levels of benzophenone 2 in
the body after its dermal administration, the first aim of the
current research was to determine its level in blood, peripheral
tissues (liver, adipose tissue), and in brain structures (frontal
cortex, hippocampus, cerebellum) after 4-week topical admin-
istration. The liver was chosen for the study because it is
responsible for metabolism of xenobiotics, and, therefore,
usually, they are present in high concentrations in this organ.
Also in adipose tissue, due to the lipophilic nature of BP-2 and
its possible accumulation, we expected to find relatively high
levels of this compound (Wang et al. 2015a). Among brain
structures, the cerebellumwas chosen, as a tissue less sensitive
to the neurotoxic effects of xenobiotics and frontal cortex and
hippocampus, because they are most vulnerable to damage.
The second objective of the present study was to demonstrate
whether benzophenone-2 administered dermally for 4 weeks
induces changes, which evidence damage to the tissues in the
most vulnerable brain structures, i.e., in the frontal cortex and
hippocampus. Since the main cause of neuronal injury is ox-
idative stress and a reduction in concentrations of already low
brain levels of antioxidant enzymes, therefore, to evaluate a
potential adverse BP-2 effect on brain structures, the produc-
tion of reactive oxygen species (ROS), total antioxidant activ-
ity, and lipid peroxidation were assayed. Oxidative stress is
the main cause of the induction of apoptosis which plays the
main role in pathogenesis of neurodegenerative disorders
(Radi et al. 2014). Therefore, in order to demonstrate whether
the excessive exposure to BP-2 may be involved in induction
or exacerbation of neurodegenerative changes, we also inves-
tigated the effect of this compound on apoptotic markers, such
as active form of caspase-3, pro-apoptotic protein (Bax), and
anti-apoptotic protein (Bcl-2).
Materials and Methods
Materials
Benzophenone-2 (2,2′,4,4′-tetrahydroxybenzofenone CAS
No 131-55-5) was purchased from Sigma Chemical Co. (St.
Louis, MO).
Animal Treatment
The experiments were performed on male Wistar rats (225–
250 g) delivered from the animal house facility of the
Jagiellonian University Medical College in Cracow. The ani-
mals were kept under natural day-night cycle, at 22 ± 2 °C
with food and water available at libitum. All procedures were
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conducted according to the NIHGuide for the Care and Use of
Laboratory Animals and were approved by the local ethics
committee. The rats were randomly divided into two groups
of ten animals in each; the first group was treated with gel with
BP-2 and the second group with pure gel.
Hair on the back of the neck through half-way towards the
tail region was shaved off prior to treatment. Animals were
reshaved during the course of treatment as soon as the hair
began to reappear. BP-2 was dissolved in small amount of
ethanol and olive oil and formulated with Hascobase
(Hasco-Lek, Poland) to the ointment and was applied at a dose
100 mg/kg twice a day (8:00 and 17:00) for 4 weeks. Control
animals were administered Hascobase with a small amount of
ethanol and olive oil. Prior to each application of BP-2, the
skin was cleaned with gauze soaked in distilled water. The
chemical was then applied gently and spread thinly over the
shaved areas of the skin. Body weights of rats were recorded
on weekly basis and on the day of sacrifice.
BP-2 or Hascobase without this compound was applied for
4 weeks twice a day, and the animals were killed 24 h after the
last dose. The animals were observed daily for any clinical
signs of impairment of health.
Tissue Collection
Twenty-four hours after last BP-2 administration, animals
were killed under non-stress conditions by rapid decapitation
and blood was collected in anticoagulant tubes. Brain regions
(hippocampus, frontal cortex, and cerebellum) and peripheral
tissues (liver, adipose tissue) were dissected on ice-cold glass
plates and stored at − 80 °C until they were used for biochem-
ical assays.
LC/MS Analysis
LC/MS-grade methanol, heptane, ethyl acetate were obtained
from Sigma-Aldrich (St. Louis, USA). LC/MS-grade glacial
acetic acid was obtained from Chempur (Piekary Śląskie,
Poland). Benzophenone-2 was purchased from Sigma
Chemical Co. (St. Louis, MO). Benzophenone-d10 from
Sigma-Aldrich (St. Louis, USA) was used as an internal stan-
dard (IS) with isotope labeling. A working internal standard
solution of BP-d10 was prepared at a concentration 25 μg/ml
in LC/MS grade methanol. All standards were stored at −
20 °C in the dark.
Frozen tissues were weighed, thawed at room temperature,
and homogenized in water in proportion 10 mg tissue (liver,
adipose tissue) or 20 mg tissue (frontal cortex, hippocampus,
cerebellum) per 200 μl of water. Plasmawasmixed with water
in proportion 1:1. Next, 200 μl of homogenate or diluted
plasma was mixed with 2 μl of internal standard in methanol
and 200 μl of water. A 1.5-ml mixture heptane and ethyl
acetate (1:1; v/v) were added, and the samples were shaken
for 10 min on an oscillating shaker. The samples were then
centrifuged for 10 min at 4000×g and the organic layer was
collected. The organic phase was evaporated to dryness under
a stream of nitrogen at 37 °C. The residues were reconstituted
in 100 μl of methanol and subjected to chromatographic
analysis.
Additionally, to assess the level of total BP-2 (parent com-
pound and its metabolites—glucuronide and sulfate) liver was
homogenized in 1 M ammonium acetate buffer, pH 5.0 in
proportion 10 mg tissue per 200 μl of buffer and plasma was
mixed with 1 M ammonium acetate buffer in proportion 1:1.
Immediately prior to the incubation for deconjugation to all
samples, 10 μl of freshly prepared enzyme mixtures (20 v/v%
β-glucuronidase and 20 v/v% sulfatase dissolved in 1 M am-
monium acetate buffer, pH 5.0) for 200 μl of homogenate
were added. The samples were mixed and incubated for 6 h
in water bath. The enzyme reaction was terminated by frozen
in − 80 °C.
The chromatographic separation was performed on an
Agilent HPLC 1100 series system (Agilent, Waldbronn,
Germany), which was equipped with a degasser, a binary
pump, an auto-sampler, and a thermostated column compart-
ment, as we described previously (Smaga et al. 2017). The
tissue sample was separated on a Xterra RP18 (Waters) col-
umn (100mm× 3.0mm ID, 3.5 μmparticle size). The column
was thermostated at 30 °C. The mobile phase was composed
of 0.25% glacial acetic acid in water (B) and methanol (A)
using the following gradient program: 0–1.5 min, isocratic
gradient 40.0% (A); 1.5–2.5 min, linear gradient 40.0–
95.0% (A); 2.50–6.50 min, isocratic gradient 95.0% (A);
6.5–8.0 min, linear gradient 95.0–40.0% (A); 8.0–10.0 min,
isocratic gradient 40.0% (A); the flow rate was 0.4 mL/min;
the injection volume was 40 μL.
Mass spectrometric analyses were accomplished on an
Applied Biosystems MDS Sciex (Concord, Ontario, Canada)
API 2000 triple quadrupole mass spectrometer equipped with
an electrospray ionization (ESI) interface. ESI ionization was
performed in the positive ionization mode. High-purity nitro-
gen used as a sheath gas was generated with a nitrogen gen-
erator. All experiments were carried out in the positive ion
mode. The ion source parameters were as follows: ion spray
voltage (IS) 5000 V; nebulizer gas (gas 1) 20 psi; turbo gas
(gas 2) 10 psi; temperature of the heated nebulizer (TEM)
250 °C; curtain gas (CUR) 20 psi. Nitrogen (99.9%) from
Peak NM20ZA was used as the curtain and collision gas.
The ion path parameters for BP-2 and BP-d10 were as fol-
lows: declustering potential (DP) 8 V; focusing potential (FP)
380 V; entrance potential (EP) 10 V; collision cell entrance
potential (CEP) 13 V; collision cell exit potential (CXP) 18 V,
respectively. The quantization analysis was performed using
the MRM mode and tandem LC/MS. The following pairs of
ions were monitored with the following values of m/z: 247.0/
137.1 for BP-2 and 193.0/110.0 for BP-d10. Data were
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analyzed by using the Analyst software 1.6 (Perlan
Technologies). The levels of benzophenone-2 were calculated
using the calibration standard curves, constructed by linear
regression analysis of peak area versus concentration curves.
ROS Assay
Brain structures were homogenized in an ice-cold 0.1 M
phosphate-buffered solution (PBS, pH 7.4). The homogenates
were centrifuged at 13,000 rpm for 20 min at 4 °C. The su-
pernatants were maintained at − 80 °C until being used for
biochemical analysis.
Briefly, the fluorescence dye DCFH-DAwas de-acetylated
by cellular esterases into a non-fluorescent compound that
could be oxidized by ROS into 2′,7′-dichlorofulorescein
(DCF). To determine the influence of BP-2 on reactive oxygen
species (ROS) production, supernatants of brain structures
were t ransfer red wi th 10 μM solut ion of 2 ′ ,7 ′ -
dichlorodihydrofluorescein (DCFH-DA) diacetate to black
96-well plates. DCFH-DA solution was co-incubated at
37 °C for 20 min, than cooled in an ice-bath for 15 min.
DCF fluorescence was measured using a fluorescence plate
reader (Fluoroskan Ascent FL, Thermo Labsystems) at
485 nm excitation and 535 nm emission wavelengths. ROS
production in samples was calculated from the standard curve
and was expressed as nmol of ROS per mg of protein.
Lipid Peroxidation (MDA) Level
Fluorometric assay for lipid peroxidation was performed
using lipid peroxidation (MDA) colorimetric/fluorometric as-
say kit (BioVision). The assay is based on the reaction of the
main product of the lipid peroxidation-malondialdehyde
(MDA) with thiobarbituric acid (TBA) at 95 °C for 60 min.
The product of this reaction MDA-TBA adduct can be quan-
tified colorimetrically (OD 532 nm) or fluorometrically (Ex/
Em = 532/553). The fluorescence was measured by a fluores-
cence plate reader (Fluoroskan Ascent FL; Thermo
Labsystems). Lipid peroxidation in samples was calculated
from the standard curve and expressed as nmol of MDA/mg
of protein.
Total Antioxidant Capacity
Analysis of total antioxidant capacity (TAC) was carried out
on the brain structure homogenates according to the modified
method of Benzie and Strain (1996) adapted to specific tissue
and microplate assay. The tissue antioxidant capacity was
evaluated by reduction of ferric ions. Fe(III)–tripyridyltriazine
(Fe(III)–TPTZ) complex was reduced to blue Fe(II)–
tripyridyltriazine (Fe(II)–TPTZ), the level of which was deter-
mined spectrophotometrically at 573 nm. The absorbance was
measured by a multiwell plate reader (TECAN Infinite M200
PRO). The total antioxidant capacity of samples was calculat-
ed from the standard curve and expressed as μmol Fe(II) per
mg of protein.
Determination of Active Form of Caspase-3,
Pro-Apoptotic Protein (Bax), and Anti-Apoptotic
Protein (Bcl-2)
Apoptotic markers were determined by Western blot method,
as we described previously (Pomierny et al. 2016). Fragments
of the frontal cortex and hippocampal tissues were homoge-
nized in 2% SDS containing 1 mM PMSF, 1 mM Na2VO4,
20 mM NaF, and mixture of phosphatase and proteinase in-
hibitors (Sigma-Aldrich) using Ultra-Turrax and ultrasonic
homogenizers. Homogenates were then denatured for
10 min at 95 °C, and insoluble material was discarded by
centrifugation at 10,000 rpm for 10 min at 4 °C. Ten microli-
ters of supernatants were used for protein determination and
after adjusting to a proper protein concentration, solutions
were mixed with loading buffer (containing 10% 2-
mercaptoethanol) at the ratio of 1:1 and heated at 95 °C for
10 min. Samples were stored at − 80 °C. Protein samples were
loaded on the gradient 8–16% SDS polyacrylamide gels (Bio
Rad Corp.) at the concentration of 30 μg/10 μl and electro-
phoreses (140 V, 1 h) were performed. Proteins were trans-
ferred to PVDF membranes on ice at 110 V for 1 h.
Membranes were then blocked in 5% nonfat milk prepared
in TBST. Particular membranes were incubated overnight at
4 °C with solutions of primary antibodies in 1% nonfat milk
against: Bcl-2 and Bax (Santa Cruz Biotechnology, mouse
monoclonal antibodies at the concentration of 1:500) and ac-
tive form of caspase-3 (Santa Cruz Biotechnology, rabbit
polyclonal antibody at the concentration of 1:700). After over-
night incubation membranes were washed twice in TBST,
twice in 1% nonfat milk, and incubated with 1% nonfat milk
solution of respective secondary antibodies conjugated with
peroxidase-anti-mouse (1:5000, Santa Cruz Biotechnology)
or anti-rabbit (1:5000, Santa Cruz Biotechnology) for 1 h in
the room temperature. After washing in TBST, membranes
were developed using ECL method (Western Bright
Quantum, Advansta Inc., USA), and the membrane chemilu-
minescence was imaged with G-Box Imaging System
(Syngene, USA). The expression of particular proteins was
analyzed with Gene Tools software (v. 4.03, Syngene, USA)
and expressed as relative to total protein (staining with
Pierce™ Reversible Protein Stain Kit for PVDF Membranes,
Thermo Fisher Scientific).
Brain Protein Concentration
Protein concentration in the brain structure homogenates was
determined using bicinchoninic acid. This method combines
reduction of Cu+2 to Cu+1 by protein in an alkaline medium
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(the biuret reaction) with the colorimetric detection of the
cuprous cation (Cu+1) using the bicinchoninic acid. The
purple-colored reaction product of this assay is formed by
the chelation of two molecules of BCA with one cuprous
ion. This water-soluble complex exhibits a strong absorbance
at 562 nm, which is linear with increasing protein concentra-
tions. The absorbance was measured by a multiwell plate
reader TECAN Infinite M200.
Statistical Analysis
All data were expressed as the means (±SEM) from ten sam-
ples assayed in duplicates. Statistical analyses were performed
with a one-way analysis of variance (ANOVA) and next, dif-
ferences between groups were evaluated by the Dunnett’s post
hoc test. p < 0.05 was considered as statistically significant.
Results
A 4-week twice a day, dermal administration of
benzophenone-2 at a dose of 100 mg/kg did not significantly
alter the body weight or cause any apparent adverse effects,
compared to control animals receiving only the base.
Concentration of Benzophenone-2 in Plasma,
Peripheral Tissues, and Brain Structures
Based on chromatograms of reference standards, the peak
with the retention time of 5.4–5.8 min was identified as BP-
2 (Fig. 1a). A molar mass of this peak was 246 g/mol, and this
value corresponds to the molar mass of the BP-2. The LC/MS
chromatograms of plasma, liver, adipose tissue, frontal cortex,
hippocampus, and cerebellum from BP-2-treated animals
showed a single peak with the retention time about 5.8 min,
which was not detectable in samples from control animals.
Representative chromatograms of serum and liver sample
from control and BP-2-treated animals are shown in Fig. 1b,
d. After hydrolysis with β-glucuronidase and sulfatase, the
BP-2 peak was significantly higher than in the same serum
and liver samples before hydrolysis (Fig. 1c, e).
Calculation of benzophenone-2 concentration from the cal-
ibration standard curves revealed that the test compound was
present in the plasma of treated animals in a concentration
range from 164 to 648 ng/ml (the average 324 ng/ml;
1.3 μM) (Fig. 2). After hydrolysis, the concentration of this
compound was 2218 ng/ml (9 μM), which indicated that in
blood, there was more BP-2 metabolites than the parent com-
pound (Fig. 2). Also in the liver, the BP-2 concentration after
hydrolysis was much higher (3758 ng/g) than the free form of
this compound (1482 ng/g) (Fig. 2), although in this tissue, the
free form was ca. 40% of the total form while in serum, only
about 15% of the total BP-2 occurred in unmetabolized form.
Since the biological effect is induced by free BP-2, in other
tissues, only this form was determined. It was found that the
average concentration of this compound in adipose tissue was
823 ng/g; in the cerebellum and frontal cortex, it was 19 ng/g;
and in the hippocampus 5 ng/g (Fig. 2).
The present study showed that after the dermal 4-week BP-2
administration, this compound in the examined peripheral tissues
was present at micromolar concentrations (5.5 μM in the liver,
3.3μMin adipose tissue), whereas in the brain structures atmuch
lower concentrations (0.08 μM in the cerebellum and frontal
cortex and 0.02 μM in the hippocampus). BP-2 concentrations
in all examined tissues in control animals were below the detec-
tion limit, but in animals receiving this compound, BP-2 was
present in plasma, liver, and adipose tissue in all animals, where-
as among brain structures, this compound was below the detec-
tion limit in the cerebellum and frontal cortex in one rat and in the
hippocampus in two animals.
The Effect of BP-2 on Reactive Oxygen Species, Total
Antioxidant Capacity, and Lipid Peroxidation
To determine whether BP-2 influences the oxidative stress pa-
rameters in the most sensitive brain structures, the level of re-
active oxygen species (ROS), total antioxidant capacity (TAC),
and lipid peroxidationwere determined in the hippocampus and
frontal cortex. In control animals, the levels of ROS and TAC
were slightly higher in the frontal cortex than in the hippocam-
pus, whereas concentration of MDA, a product of lipid perox-
idation was about 2-fold higher in the hippocampus than in the
frontal cortex. It was found that BP-2 administration did not
significantly affect any of the examined oxidative stress
markers in the hippocampus (Fig. 3) and even a tendency to
decrease the level of ROS and lipid peroxidation was observed
in BP-2-treated rats in comparison to control animals. In the
second of the examined brain structures, frontal cortex, a statis-
tically significant decrease in ROS production (about 26%) and
increase of total antioxidant activity (about 31%) was demon-
strated (Fig. 3). The level of the main polyunsaturated fatty acid
peroxidation product malondialdehyde (MDA) was significant-
ly lower (about 10%) in the frontal cortex of BP-2-treated rats
than in control animals (Fig. 3).
The Effect of BP-2 on Apoptotic Markers
To determine whether BP-2 can affect process of apoptosis, the
active form of caspase-3 (17 kDa fragment created by cleavage
of caspase-3), main anti-apoptotic (Bcl-2), and primary pro-
apoptotic (Bax) proteins were determined byWestern blot meth-
od in the hippocampus and frontal cortex in BP-2-treated and
control animals.We have shown that BP-2 administration did not
change in statistically significant manner the concentrations of
any of the examined apoptotic markers, neither in the hippocam-
pus nor in the frontal cortex (Table 1).
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Discussion
The present study demonstrates that BP-2 is absorbed through
the skin and occurs in micromolar concentrations in the blood,
liver, and adipose tissue. We provide also the evidence that
this compound passes through the blood-brain barrier and is
present in varying, but relatively low, concentrations in the
certain brain structures. The obtained results also show that
after 4 weeks of dermal exposure of rats to BP-2, the concen-
tration of this compound in the brain is too low to induce
oxidative stress or induce apoptosis in the hippocampus and
frontal cortex.
To the best of our knowledge, this is the first study in
which concentrations of BP-2 in plasma, peripheral tissues,
and brain structures were determined after dermal sub-
chronic application of this compound. To date, only serum
BP-2 concentration was determined in rats after a short, 5-
day administration of this compound per gavage (Schlecht
et al. 2008). We found that 24-h after last, dermal BP-2 ap-
plication, plasma concentration of this compound was
324 ng/ml, whereas after hydrolysis, total level of this com-
pound was ca. 7-fold higher than free form of BP-2. These
results are consistent with data obtained in rats after oral
administration of this compound, which showed that in se-
rumandurine,BP-2metaboliteswere present atmuch higher
concentration than free BP-2 (Schlecht et al. 2008). The
existing data on the BP-2 metabolism are scarce, but it was
stated that in zebrafish, BP-2 was exclusively metabolized
through phase II, but not by phase I reaction (Le Fol et al.
2017). Research described by Schlecht et al. (2008) indicate
Fig. 1 A representative chromatogram of BP-2 standard (a) and serum of BP-2 treated rats without (b) and after (c) glucuronide and sulfate hydrolysis,
and liver without (d) and after (e) hydrolysis
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that also in the rat, BP-2 is metabolized only via phase II, and
specifically, after oral administration, this compound is rap-
idly conjugated mainly with glucuronate and to a smaller
extent with sulfate and excreted with urine. We found that
more BP-2 in the form of conjugates occurred in the serum
than in the liver, the main organ involved in metabolism of
xenobiotics, which suggests that themetabolismof this com-
pound also occurs in other organs. The gut can be another
probable organ of BP-2 metabolism, because synthetic ste-
roids, for which benzophenones show structural similarity,
were reported to bemetabolizedmainly in the gut (Back et al.
1990). The relatively high concentration of BP-2 occurred in
adipose tissue, indicating that, like other lipophilic xenobi-
otics, this compound is accumulated in this tissue.
The obtained data showed that 24 h after the last dermal
administration of BP-2, its concentrations in blood and periph-
eral tissues, such as liver and adipose tissue, were relatively
high. As for serum, similar BP-2 levels as in the present study
have been demonstrated after oral administration of this com-
pound, but only for a short time after administration. After oral
administration, the maximum BP-2 concentration in serum
was observed after 30 min and depending on the dose, it
ranged from 0.1 to 1.1 μg/ml (Schlecht et al. 2008), whereas
in the case of dermal administration, the BP-2 level of about
0.3 μg/ml was observed 24 h after the last injection,
suggesting a slower metabolism of the test compound after
dermal than oral administration. High concentrations of BP-
2 were observed in the liver, which is presumably due to the
fact that this compound is metabolized in this organ and in
adipose tissue, which is more likely connected with accumu-
lation (Wang et al. 2015a). Many studies conducted on fish
indicate that benzophenones are cumulated mainly in this tis-
sue. As a lipophilic compound, BP-2 is not only accumulated
in adipose tissue but also should cross blood-brain barrier. The
present study provided evidence that it actually reached the
brain tissue, but it was found in brain structures, especially in
the hippocampus, rather at low concentrations. Because the
BP-2 level was measured only at one time point, after a rela-
tively long time after its administration, it can be assumed that
in earlier time points, its concentration might be higher. Of the
brain structures most susceptible to damage, higher levels of
BP-2 occurred in the frontal cortex than in the hippocampus,
which is consistent with the often observed phenomenon of
greater distribution of lipophilic xenobiotics in the cerebral
cortex than in subcortical areas.
The obtained results showed that after 2-week dermal ad-
ministration of BP-2, the concentrations of this compound in
the examined tissues were different. The highest concentration
was observed in the liver, which is well-perfused and
possessing a strong metabolic capacity tissue. In contrast to
Fig. 2 Concentrations of free BP-2 in serum, liver, adipose tissue,
cerebellum, frontal cortex, and hippocampus and total BP-2
concentrations after glucuronide and sulfate hydrolysis in serum and
liver. Rats were treated dermally with 100 mg/kg BP-2 twice a day for
4 weeks and were killed 24 h after the last BP-2 application. Data are
expressed as the means ± SEM and were statistically evaluated by one-
way analysis of variance (ANOVA), followed by Duncan’s post hoc test.
*p < 0.05 vs. control animals, n = 10
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the liver, the adipose tissue and brain have a low metabolic
phase II capacity and in these tissues, BP-2, like other EDC
with similar chemical structure, should be present mainly in
free but not conjugated form (Geens et al. 2012). Despite the
fact that BP-2 is a lipophilic compound, its concentration in
the adipose tissue was a little lower and in the brain much
lower than the level of the free form of this compound in more
hydrophilic organs, especially in the liver. The unexpectedly
low BP-2 concentration in the brain is difficult to explain, but
it may be due to its limited ability to pass through the blood-
brain barrier or the rapid removal of this compound by trans-
porters present in the blood-brain barrier. BP-2 is a less lipo-
philic compound than benzophenone-3 (BP-3), which as
shown by our unpublished data, reaches in the rat brain ap-
proximately 2.5-fold higher concentration than the BP-2.
Differences in octane/water partition coefficients may account
for differences in brain concentrations between BP-3 (log
Fig. 3 The effect of BP-2 on
reactive oxygen species (ROS)
level in the frontal cortex and
hippocampus, on total antioxidant
capacity (TAC) in the frontal
cortex and hippocampus and lipid
peroxidation in the frontal cortex
and hippocampus. Rats were
treated dermally with 100 mg/kg
BP-2 twice a day for 4 weeks and
were killed 24 h after the last BP-
2 application. Data are expressed
as the means ± SEM and were
statistically evaluated by one-way
analysis of variance (ANOVA),
followed by Duncan’s post hoc
test. *p < 0.05 vs. control animals,
n = 10
Table 1 The effect of benzophenone-2 (BP-2) on expression of active
form of caspase-3, pro-apoptotic (Bax), and anti-apoptotic (Bcl-2)
proteins in the frontal cortex and hippocampus. Rats were treated
dermally with 100 mg/kg BP-2 twice a day for 4 weeks and were killed
24 h after the last BP-2 application. Data are expressed as the means ±
SEM and were statistically evaluated by one-way analysis of variance
(ANOVA), followed by Duncan’s post hoc test (n = 10)
Control BP-2
Frontal cortex
Caspase-3 active 100 ± 10.22 92.1 ± 11.51
Bax 100 ± 7.1 107.7 ± 7.5
Bcl-2 100 ± 5.51 103.2 ± 8,56
Hippocampus
Caspase-3 active 100 ± 11.41 112.2 ± 7.62
Bax 100 ± 7.62 88.22 ± 4.48
Bcl-2 100 ± 8.65 102.6 ± 11.25
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Kow about 3.6) and BP-2 (log Kow about 3.2); however, the
relatively low concentrations of both BP-2 and BP-3 in the rat
brain suggest that these compounds could be removed by
some blood-brain barrier transporters. As in the case of BP-
2, also another EDC-bisphenol-A, with a structure similar to
benzophenones poorly penetrates into the brain, which also
suggests that, unlike endogenous estrogens, transport to the
brain of xenobiotics showing affinity for estrogen receptors
may be limited (Sun et al. 2002). Like the blood-brain barrier,
also the placental barrier seems to give some protection of the
fetuses against certain benzophenones (Krause et al. 2018).
In the second part of this study, we determined potential
adverse effects of BP-2 on oxidative stress and apoptotic
markers in the frontal cortex and hippocampus, which are
the structures especially vulnerable to damage. Contrary to
predictions, in none of these brain regions, changes in ox-
idative stress and apoptotic markers were observed, which
would indicate the induction of cell damage. We have
found that 4-week dermal administration of BP-2 did not
change the level of the active form of caspase-3, executive
enzyme in apoptotic process, or key proteins regulating
apoptosis in both brain regions. Thus, the obtained results
did not confirm our previous data from in vitro study
(Broniowska et al. 2016). In previous studies, we have
shown that BP-2 present in culture medium for 72 h in
concentrations range from 0.1 to 100 μM induces apopto-
sis in human neuroblastoma cell line—SH-SY5Y. In the
case of the hippocampus, in this structure, BP-2 was pres-
ent at a concentration of ca. 0.02 μM, so at a concentration
lower than the concentrations that induced apoptosis in
SH-SY5Y cells. However, in the frontal cortex, BP-2 con-
centration was only slightly lower (0.08 μM) from concen-
trations that induced apoptosis in SH-SY5Y cells.
Interestingly, in the frontal cortex, not only no changes in
the apoptosis markers were observed, but even BP-2
caused beneficial changes in oxidative stress markers.
This compound reduced the level of ROS, enhanced total
antioxidant capacity, and lowered lipid peroxidation, so to
a certain extent, it augmented the endogenous mechanisms
of neuroprotection. Induction of total antioxidant activity
by BP-2 was probably the cause of inactivation and reduc-
tion in ROS level and in consequence decreasing lipid per-
oxidation. The increase in total antioxidant capacity may
result from intensification of synthesis of endogenous an-
tioxidant enzymes or non-enzymatic antioxidants. Unlike
in the frontal cortex, in the hippocampus, there were no
changes in the oxidative stress markers, which may be
due to low BP-2 levels in this structure.
The beneficial effect of BP-2 in the frontal cortex is diffi-
cult to explain especially because previous data have shown
that another compound from the benzophenone group, i.e.,
benzophenone-3 induced strong neurotoxic effects in this
structure (Krzyżanowska et al. 2018; Wnuk et al. 2018). The
difference in the effects of these compounds results probably
from their penetration into the CSN and from their different
chemical structures. BP-2 is less l ipophil ic than
benzophenone-3 which may be the main reason for its poorer
penetration to the brain and, therefore, lack of neurotoxic ef-
fect. On the other hand, it is known that even a slight change in
the structure of the compound can significantly alter its bio-
logical effects. For example, examining the effect of different
fluorinated benzophenone derivatives in in vitro models, it has
been shown that depending on the chemical structure, some of
them exhibit antioxidant properties (Belluti et al. 2014). Based
on the existing data, it is not possible to determine whether the
antioxidant effects of BP-2 in the frontal cortex result from the
activation of endogenous, antioxidant mechanisms triggered
by low concentrations of neurotoxic compounds or is the re-
sult of the antioxidant properties of this compound; however,
since the BP-2 in vitro produces a distinct pro-apoptotic effect,
the former suggestion is more likely.
In conclusion, the present study showed that BP-2 was
absorbed through the rat skin and passed through the blood-
brain barrier, but its concentration in the brain was much lower
than in the periphery. In the animal model used, BP-2 did not
show pro-oxidative or pro-apoptotic effects in the hippocam-
pus and frontal cortex, and in the frontal cortex even reduced
the parameters of oxidative stress.
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